Henderson Molly
SEC CIK 1363812 · EDGAR
BoughtSold
Most active insiders at PHAT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Breedlove Robert Charles | Principal Accounting Off | — | $7,079 |
| 2 | Narula Sanjeev | Chief Financial, Bus. Off | — | — |
| 3 | Parikh Asit | Dir | — | — |
| 4 | Stenhouse Mark | Dir | — | — |
| 5 | Basta Steven L | Pres, CEO, Dir | — | — |
| 6 | Schroeder Theodore R | Dir | — | — |
| 7 | Topper James N | Dir, 10% | — | — |
| 8 | Cook Anne Marie | Chief Legal Off, Corp. Sec | — | — |
| 9 | KARBE FRANK | Dir | — | — |
| 10 | COLA MICHAEL F | Dir | — | — |
Henderson Molly made no open-market trades at PHAT in the last 12 months.
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-08 | 2025-04-07 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $4.55 | -3,678 | 89.9K | -4% | -$16.7K | |
| D | 2025-03-03 | 2025-02-27 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +72.0K | 165.5K | +77% | $0 |
| 2025-01-23 | 2025-01-21 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $6.59 | -6,583 | 93.5K | -7% | -$43.4K | |
| 2024-12-20 | 2024-12-19 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $8.00 | -1,291 | 98.2K | -1% | -$10.3K | |
| 2024-07-17 | 2024-07-15 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $11.72 | -4,325 | 99.4K | -4% | -$50.7K | |
| 2024-05-31 | 2024-05-31 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +7,500 | 102.8K | +8% | $0 | |
| 2024-04-10 | 2024-04-08 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $11.10 | -3,435 | 95.3K | -3% | -$38.1K | |
| D | 2024-01-22 | 2024-01-19 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $7.75 | -6,307 | 98.7K | -6% | -$48.9K |
| 2023-11-21 | 2023-11-20 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $7.24 | -2,127 | 103.1K | -2% | -$15.4K | |
| 2023-11-03 | 2023-11-01 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +22.5K | 117.7K | +24% | $0 | |
| M | 2023-11-03 | 2023-11-01 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $8.88 | -12.5K | 105.2K | -11% | -$110.9K |
| A | 2023-07-21 | 2023-07-14 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +25.0K | 95.2K | +36% | $0 |
| 2023-07-17 | 2023-07-14 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $1.00 | +25.0K | 95.2K | +36% | +$25.0K | |
| 2023-06-05 | 2023-06-02 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $11.41 | -1,960 | 68.5K | -3% | -$22.4K | |
| 2023-05-23 | 2023-05-22 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $12.87 | -2,110 | 70.5K | -3% | -$27.2K | |
| 2023-04-07 | 2023-04-06 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $7.27 | -3,439 | 72.6K | -5% | -$25.0K | |
| 2023-03-03 | 2023-03-01 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $8.53 | -2,032 | 76.0K | -3% | -$17.3K | |
| D | 2023-01-20 | 2023-01-19 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +33.0K | 78.0K | +73% | $0 |
| 2022-11-23 | 2022-11-21 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $9.60 | -2,159 | 43.3K | -5% | -$20.7K | |
| 2022-09-02 | 2022-09-01 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +7,500 | 45.5K | +20% | $0 | |
| 2022-05-20 | 2022-05-19 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +12.0K | 38.0K | +46% | $0 | |
| 2022-05-16 | 2022-05-13 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | P - Purchase | — | +6,000 | 26.0K | +30% | — | |
| D | 2022-04-06 | 2022-04-05 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2022-02-02 | 2022-01-31 | URGN | UroGen Pharma Ltd. | Henderson Molly | CFO | S - Sale+OE | $7.58 | -331 | 5,248 | -6% | -$2,509 |
| D | 2022-02-02 | 2022-01-31 | URGN | UroGen Pharma Ltd. | Henderson Molly | CFO | M - OptEx | — | +666 | 5,579 | +14% | — |
| D | 2021-12-02 | 2021-11-30 | URGN | UroGen Pharma Ltd. | Henderson Molly | CFO | S - Sale+OE | $12.03 | -2,587 | 4,913 | -34% | -$31.1K |
| D | 2021-12-02 | 2021-11-30 | URGN | UroGen Pharma Ltd. | Henderson Molly | CFO | M - OptEx | — | +5,000 | 7,500 | +200% | — |
Purchase Sale Sale after option exercise All abbreviations